Request Demo
Last update 12 Jan 2026
HX-111
Last update 12 Jan 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms HX 111, HX111 |
Target |
Action inhibitors |
Mechanism OX40 inhibitors(Tumor necrosis factor receptor superfamily member 4 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
2
Clinical Trials associated with HX-111NCT07333469
A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of HX111 in Patients With Advanced Solid Tumor and Lymphoma
CTR20255147
一项在晚期实体瘤和淋巴瘤患者中评价 HX111 安全性、耐受性、药代动力学和临床疗效的 I/IIa 期研究
[Translation] A phase I/IIa study evaluating the safety, tolerability, pharmacokinetics, and clinical efficacy of HX111 in patients with advanced solid tumors and lymphoma.
100 Clinical Results associated with HX-111
Login to view more data
100 Translational Medicine associated with HX-111
Login to view more data
100 Patents (Medical) associated with HX-111
Login to view more data
100 Deals associated with HX-111
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anaplastic Large-Cell Lymphoma | Phase 2 | - | 19 Jan 2026 | |
| Extranodal NK-T-Cell Lymphoma | Phase 2 | - | 19 Jan 2026 | |
| Immunoblastic Lymphadenopathy | Phase 2 | - | 19 Jan 2026 | |
| Peripheral T-Cell Lymphoma | Phase 2 | - | 19 Jan 2026 | |
| Advanced Lymphoma | Phase 2 | China | 24 Dec 2025 | |
| Advanced Lymphoma | Phase 2 | Hong Kong | 24 Dec 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 24 Dec 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Hong Kong | 24 Dec 2025 | |
| Hematologic Neoplasms | IND Approval | China | 19 Dec 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free